4th Quarter - Report
WINNING STRATEGIES WASHINGTON for KALEO
Client
Income
$40,000
Expenses
—
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Economics/Economic Development ECN
CARES Act Implementation
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A MEROLA | Deputy CoS, Sen. Torricelli |
| CHARLA PENN | LA, Rep. Pascrell; SA/LC/LA, Rep. Boyd |
| CHELSEY PENROD HICKMAN | CoS, Rep. Kay Granger; LA Sen. Larry Craig |
| ROBERT ZUCKER | LD, Rep. Rothman; LA,Rep. Evans (IL); Sen. Lautenberg |
Health Issues HCR
Legislation related to prescription drug prices, including H.R. 3
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A MEROLA | Deputy CoS, Sen. Torricelli |
| CHARLA PENN | LA, Rep. Pascrell; SA/LC/LA, Rep. Boyd |
| CHELSEY PENROD HICKMAN | CoS, Rep. Kay Granger; LA Sen. Larry Craig |
| ROBERT ZUCKER | LD, Rep. Rothman; LA,Rep. Evans (IL); Sen. Lautenberg |
Aviation/Airlines/Airports AVI
Epinephrine in airline medical kits
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A MEROLA | Deputy CoS, Sen. Torricelli |
| CHARLA PENN | LA, Rep. Pascrell; SA/LC/LA, Rep. Boyd |
| CHELSEY PENROD HICKMAN | CoS, Rep. Kay Granger; LA Sen. Larry Craig |
| ROBERT ZUCKER | LD, Rep. Rothman; LA,Rep. Evans (IL); Sen. Lautenberg |
Pharmacy PHA
Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL A MEROLA | Deputy CoS, Sen. Torricelli |
| CHARLA PENN | LA, Rep. Pascrell; SA/LC/LA, Rep. Boyd |
| CHELSEY PENROD HICKMAN | CoS, Rep. Kay Granger; LA Sen. Larry Craig |
| ROBERT ZUCKER | LD, Rep. Rothman; LA,Rep. Evans (IL); Sen. Lautenberg |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.